KRAS Mutation Analysis
Alternative name:
KRAS Exons 2-4 (includes G12C mutation)
Methodology
Molecular
Test Description and clinical significance
Genes
KRAS variants in exon 2 (eg, codons 12 and 13) & additional variant(s) (eg, codon 61, codon 146)
Disease:
pancreatic and colorectal cancer, Non-small cell lung cancer & ductal carcinoma of the pancreas, cardiofaciocutaneous syndrome, Noonan syndrome, Autoimmune lymphoproliferative syndrome, Cholangiocarcinoma, Core binding factor acute myeloid leukemia, Epidermal nevus
K-Ras is an oncogene which plays a crucial role in the development of tumours. Mutations in the K-Ras gene are present in approximately 35-45% of colorectal cancers, in 15-50% of lung cancers and in 72-90% of pancreatic cancers. The mutations have been localized in various DNA sections, including codon 12 and 13. Several recently published studies have shown that the mutation status can be a prognostic marker for treatment with EGFR antibodies such as Cetuximab (Erbitux, Merck), or Panitumumab (Vectibix, Amgen)
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 ?l of each DNA with a concentration of at least 5ng/?l and an OD260/280 ratio of 1.7-1.9 and 2.0-2.1 respectively, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored DNA or RNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Genomic DNA must be stored at 2–8°C for several weeks post extraction, then at –15 to –25°C for long term storage
CPT(s)
81275, 81276
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
